Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 14/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 14/20 | 0.61 |
| ▸ | RAF1 | P04049 | 12/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.59 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.56 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 2/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.53 |
| ▸ | GCGR | P47871 | 2/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67025 | 0.96 | MAPK13 (0.61) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL67192 | 0.89 | MAPK11 (0.64) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL67680 | 0.89 | SMPD3 (0.51) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL67817 | 0.88 | NOX1 (0.50) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL68940 | 0.87 | MAPK13 (0.64) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL66226 | 0.87 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL68659 | 0.87 | MAPK13 (0.52) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL68478 | 0.87 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL67146 | 0.86 | MAPK13 (0.63) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL68402 | 0.86 | SMPD3 (0.57) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | MAPK14 484/4885MAPK13 178/4885MAPK12 501/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | MAPK14 218/4885MAPK13 197/4885MAPK12 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.